EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The role of ERK1/2 signaling in diabetes: pathogenic and therapeutic implications

Hanlin Xu, Tao Liu, Yanfen Dai, Na Li, Zhanqi Cao

Frontiers in Pharmacology · 09.05.2025 · 16

DOI: 10.3389/fphar.2025.1600251 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 09.05.2025. Verfasst von Hanlin Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ERK1/2 (extracellular signal-regulated kinase 1/2) is an important member of the MAPK (mitogen-activated protein kinase) family and is widely involved in many biological processes such as cell proliferation, differentiation, apoptosis and migration. After activation by phosphorylation, ERK1/2 can be transferred into the nucleus and directly or indirectly affect the activity of transcription factors, thereby regulating gene expression. More and more studies have shown that ERK1/2 plays an important role in diabetes and its complications, such as insulin secretion, islet β cell function, diabetic cardiomyopathy, diabetic nephropathy, renal fibrosis, lipogenesis, diabetic vasculopathy, etc. These effects reveal the complexity and diversity of the ERK1/2 signaling pathway in the pathogenesis of diabetes, and its activation and inhibition mechanisms in multiple physiological and pathological processes provide potential targets for diabetes treatment. The purpose of this mini-review is to explore the key role of ERK1/2 in diabetes and the progress of research on targeted inhibitors of ERK1/2, which provides new strategies for the treatment of diabetes.

Schlagwörter

Stichwörter der Autor:innen

ERK1/2MAPKcomplicationsdiabetesinhibitors

Autor:innen und Institutionen

  • Department of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
  • Department of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, China.
  • Department of Hyperbaric Oxygen, The Affiliated Hospital of Qingdao University, Qingdao, China.

Zitieren

APA

Xu, H., Liu, T., Dai, Y., Li, N., & Cao, Z. (2025). The role of ERK1/2 signaling in diabetes: pathogenic and therapeutic implications. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1600251

Vancouver

Xu H, Liu T, Dai Y, Li N, Cao Z. The role of ERK1/2 signaling in diabetes: pathogenic and therapeutic implications. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1600251

BibTeX
@article{Xu2025,
  author = {Xu, Hanlin and Liu, Tao and Dai, Yanfen and Li, Na and Cao, Zhanqi},
  title = {The role of ERK1/2 signaling in diabetes: pathogenic and therapeutic implications},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1600251}
}
Kostenlos starten →